DTaP-IPV-Hep B-Hib vaccine (Hexyon®/Hexacima®): a guide to its use in the primary and booster vaccination of infants and toddlers in Europe
- 188 Downloads
Hexyon®/Hexacima® (DTaP-IPV-Hep B-Hib) is a new thiomersal-free hexavalent combination paediatric vaccine indicated for the primary and booster vaccination of infants and toddlers from 6 weeks to 24 months of age in Europe. Clinical data indicate that vaccination with this vaccine is a safe and immunogenic option for providing protection against the serious childhood infections of diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b. Its fully liquid ready-to-use formulation is convenient and simplifies administration by healthcare professionals.
KeywordsPertussis Diphtheria Booster Vaccination Primary Vaccination Varicella Vaccine
The manuscript was reviewed by: G. Gabutti, Department of Prevention, O.U. Hygiene and Public Health, LHU4 “Chiavarese” - Regione Liguria, Chiavari, Italy; M.E. Pichichero, Centre for Infectious Diseases and Immunology, Rochester General Hospital, Rochester, NY, USA.
This article was adapted from Pediatric Drugs 2013;15(1):59–70 . The preparation of these reviews was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the articles. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.
- 1.World Health Organization. WHO recommendations for routine immunization: summary tables. 2012. http://www.who.int/immunization/policy/immunization_tables/en/. Accessed 12 July 2013.
- 3.Hexyon suspension for injection: summary of product characteristics. London: European Medicines Agency; 2013.Google Scholar
- 4.Hexacima suspension for injection: summary of product characteristics. London: European Medicines Agency; 2013.Google Scholar
- 8.Ceyhan M, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent fully liquid DTaP-IPV-Hep B-PRP-T vaccine given at 2, 3, 4 months of age with a booster at 15–18 months compared to licensed vaccines in Turkish infants [abstract plus poster]. 5th Asian Congress of Pediatric Infectious Diseases; 23–26 Sep 2010; Taipei.Google Scholar
- 9.Tregnaghi MW, Zambrano B, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae B conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants. Pediatr Infect Dis J. 2011;30(6):e88–96.PubMedGoogle Scholar
- 12.Kosalaraksa P, Thisyakorn U, Benjaponpitak S, et al. Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants. Int J Infect Dis. 2011;15(4):e249–56.PubMedCrossRefGoogle Scholar
- 13.Lopez P, Arguedas A, Consuelo-Miranda M, et al. Immunogenicity and safety of a primary series of a new fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine (Hexaxim™) co-administered with Prevenar™ and Rotarix™ in healthy children in Latin America [abstract no. A3L24]. 15th International Congress on Infectious Diseases; 13–16 June 2012; Bangkok.Google Scholar
- 14.Madhi SA, Koen A, Cutland C, et al. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15–18 months of age in healthy South African infants. Pediatr Infect Dis. 2013;32(8):889–97.Google Scholar
- 15.Tregnaghi M, Zambrano B, Santos-Lima E. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants. Pediatr Infect Dis J. 2012;31(1):e24–30.PubMedCrossRefGoogle Scholar
- 16.World Health Organization. Hepatitis B vaccines: WHO position paper. Wkly Epidemiol Rec. 2009;84(40):405–19.Google Scholar